Literature DB >> 9625454

Occult papillary thyroid carcinoma in Hashimoto's thyroiditis presenting as a metastatic bone tumor.

M Nishikawa1, N Toyoda, T Yonemoto, A Fujiyama, Y Ogawa, T Tokoro, N Sakaguchi, M Yoshimura, N Yoshikawa, S Tabata, H Kumazawa, T Yamashita, N Sakaida, A Okamura, K Kasagi, M Inada.   

Abstract

Some occult thyroid carcinomas are hypothesized to regress and be eventually obliterated. We report here a patient whose condition supports this hypothesis. A 51-year-old male with primary hypothyroidism due to Hashimoto's thyroiditis suffered from a rib bone tumor. He had a diffuse goiter with no nodular lesion. Serum FT4 and TSH concentrations were 0.8 ng/dl and 36.4 microU/ml on taking 100 microg/day of T4. Anti-Tg- and -TPO-Ab were strongly positive (99 and 1380 U/ml). The iodine 123 scintigraphy demonstrated clear accumulation in the rib tumor, whereas the thyroid was scarcely visible. Biopsy of the rib tumor showed papillary proliferation of large atypical cells, which were immunohistochemically positive for thyroglobulin. Metastatic bone tumor of papillary thyroid carcinoma was therefore strongly suspected. He underwent a total thyroidectomy and the thyroid was stepwise sectioned completely at 3 mm intervals. The thyroid condition was diagnosed as Hashimoto's thyroiditis demonstrating diffuse and dense fibrosis, lymphocyte infiltration with lymphoid follicles and flattened atrophied follicles, but no carcinomatous foci were found. He was treated with I-131 and scintigraphy after the ingestion showed distinct accumulation in the rib tumors similar to that before thyroidectomy. No other abnormal uptake was observed. It is suggested that the primary occult thyroid papillary carcinoma regressed and was obliterated possibly by some immunologic or other host-resistance factors after it metastasized to the distant bone.

Entities:  

Mesh:

Year:  1998        PMID: 9625454     DOI: 10.1507/endocrj.45.111

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  7 in total

1.  Occult parathyroid carcinoma in a patient with papillary thyroid carcinoma and Hashimoto's thyroiditis.

Authors:  H Savli; A Sevinc; R Sari; S Ozen; S Buyukberber; E Ertas
Journal:  J Endocrinol Invest       Date:  2001-01       Impact factor: 4.256

2.  How Many Papillae in Conventional Papillary Carcinoma? A Clinical Evidence-Based Pathology Study of 235 Unifocal Encapsulated Papillary Thyroid Carcinomas, with Emphasis on the Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features.

Authors:  Bin Xu; Rene Serrette; R Michael Tuttle; Bayan Alzumaili; Ian Ganly; Nora Katabi; Giovanni Tallini; Ronald Ghossein
Journal:  Thyroid       Date:  2019-10-10       Impact factor: 6.568

Review 3.  Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): An Update.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Head Neck Pathol       Date:  2020-03-02

4.  Metastatic thyroid carcinoma without identifiable primary tumor within the thyroid gland: a retrospective study of a rare phenomenon.

Authors:  Bin Xu; Theresa Scognamiglio; Perry R Cohen; Manju L Prasad; Adnan Hasanovic; Robert Michael Tuttle; Nora Katabi; Ronald A Ghossein
Journal:  Hum Pathol       Date:  2017-05-25       Impact factor: 3.466

5.  Recurrence after total thyroidectomy for benign multinodular goiter.

Authors:  Kylie L Snook; Peter L H Stalberg; Stan B Sidhu; Mark S Sywak; Pamela Edhouse; Leigh Delbridge
Journal:  World J Surg       Date:  2007-03       Impact factor: 3.352

6.  Occult papillary thyroid carcinoma metastasis to the sacrum and the skull: an unusual presentation.

Authors:  Fatima S Jouhar; Asif Quadri; Bachar Afandi; Sadir Al Rawi
Journal:  Case Rep Med       Date:  2014-12-08

7.  Metastatic papillary thyroid carcinoma with no primary tumor in the thyroid gland: a case report and review of literature.

Authors:  Daxue Li; Jiazhen Li; Jing Zhou; Qian Xiao; Han Gao
Journal:  Transl Cancer Res       Date:  2022-01       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.